Answers are grounded in this paper and cite their sources.
Nephrol Dial Transplant 2017 gfx043. doi: 10.1093/ndt/gfx043 In the published version of this article Table 1 contained errors in the first column. The corrected version of Table 1 is given below: Demographics characteristics at TEMPO 3:4 and TEMPO 4:4 baseline Data are given as means with standard deviation (SD), or as median with interquartile range (IQR) when appropriate. BL, baseline. The early-treatment group received tolvaptan in TEMPO 3:4 and the late-treatment group received placebo. The author apologises for this error, which has now been corrected.
No takes yet. Share an insight, caveat, or question.
Torres et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: